A 65-Year-Old Man Diagnosed with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Dr. Shore will provide his initial impressions of the patient case, including an assessment of the patient's risk level and how this influences clinical decision-making.

In this segment, Dr. Shore will offer an overview of current treatment options for metastatic hormone-sensitive prostate cancer (mHSPC), as outlined in the NCCN Guidelines for Prostate Cancer. He will discuss patient factors that guide the selection of therapeutic agents or combination therapies.

Dr. Shore will explore the evidence supporting treatment intensification through combining or sequencing therapies in metastatic prostate cancer. He will discuss the potential benefits and downsides of this approach, as well as which patients may benefit from an intensified treatment strategy.

Dr. Shore will provide an overview of the Phase 3 ARASENS trial, which evaluated the efficacy of the androgen receptor inhibitor darolutamide in combination with androgen deprivation therapy (ADT) and docetaxel in hormone-sensitive prostate cancer patients. He will discuss the potential benefits of this combination in patients with high tumor burden mHSPC.

In this segment, Dr. Shore will review the findings of several pivotal Phase 3 trials evaluating the efficacy of various treatments in metastatic hormone-sensitive prostate cancer patients, including the MAGNITUDE, PROpel, and TALAPRO-2 trials, among others.

Dr. Shore will discuss the factors that guide treatment choices for mHSPC patients with a high disease burden and comorbidities.

Dr. Shore will highlight the importance of a multidisciplinary approach in the management of patients with mHSPC and the roles of various healthcare professionals in providing comprehensive care.

In this concluding segment, Dr. Shore will share clinical pearls and practical insights regarding the optimal management of patients with metastatic hormone-sensitive prostate cancer.